Table 5. Sensitivity analysis.

Analysis	Result
Base case
Cost campaign (2006–2013)—NPV	$15,634,946
Relative risk—1.91 Mel; 1.4 BCC, 1.23 SCC
Melanoma cases and deaths averted (2006–2013)	885 cases, 109 deaths
NMSC cases and deaths averted (2006–2013)	12,289 cases, 2.6 deaths
Economic value of benefit—NPV	$60,167,541
Benefit cost ratio	3.85
Sensitivity 1—Lower relative risk
Cost campaign (2006–2013)—NPV	$15,634,946
Melanoma cases and deaths averted	687 cases, 85 deaths
NMSC cases and deaths averted (2006–2013)	7,452 cases, 0 deaths
Economic value of benefit—NPV	$42,133,964
Benefit cost ratio	2.69
Sensitivity 2 –Benefit until 2020
Cost campaign (2006–2013)—NPV	$15,634,946
Melanoma cases and deaths averted (2006–2020)	1,307 cases, 161 deaths
NMSC cases and deaths averted (2006–2020)	18,198 cases, 5 deaths
Economic value of benefit—NPV	$84,435,817
Benefit cost ratio	5.40
Sensitivity 3–5 year lag effect to benefits
Cost campaign (2006–2013)—NPV	$15,634,946
Melanoma cases and deaths averted (2011–2020)	1,272 cases, 157 deaths
NMSC cases and deaths averted (2011–2020)	17,949 cases, 3.9 deaths
Economic value of benefit—NPV	$71,010,001
Benefit cost ratio	4.54

Notes: NPV = net present value.